Acidos grasos poliinsaturados (PUFAS) en el tratamiento del déficit de atención con y sin hiperactividad (TDAH)
PDF

Palabras clave

Acidos grasos Omega-3
Nutrición
PUFAS
TDAH
Tratamiento

Cómo citar

Ruiz-Lázaro, P. M., & Grupo de Especial Interés, T. (2014). Acidos grasos poliinsaturados (PUFAS) en el tratamiento del déficit de atención con y sin hiperactividad (TDAH). Revista De Psiquiatría Infanto-Juvenil, 31(3), 11-22. Recuperado a partir de https://aepnya.eu/index.php/revistaaepnya/article/view/168

Resumen

El Trastorno por Déficit de Atención/Hiperactividad (TDAH) es muy prevalente en niños y adolescentes con factores causales ambientales y genéticos. Los ácidos grasos poli-insaturados (PUFAS) son nutrientes esenciales para los humanos. Se ha postulado que los PUFAS pueden contribuir al desarrollo del cerebro de los niños y su desequilibrio puede incrementar el riesgo de TDAH.
En recientes estudios clínicos, la suplementación con PUFAS mejora síntomas de TDAH en algunos casos. En este momento los hallazgos de los ensayos controlados aleatorizados son demasiado limitados y no apoyan de forma definitiva el uso generalizado en la práctica clínica de los ácidos grasos esenciales (omega-3 y 6) como tratamiento primario o suplementario en los niños con TDAH.
La eficacia relativa de la suplementación con PUFAS es modesta si se compara con el tratamiento farmacológico del TDAH con psicoestimulantes, atomoxetina o α(2) agonistas. Ante su perfil relativamente benigno de efectos adversos y las pruebas de cierta eficacia, puede ser razonable el uso de PUFAS para potenciar las intervenciones farmacológicas tradicionales o en familias que rechazan las opciones farmacológicas.
Si se decidiera emplearlos debería usarse de forma preferente la combinación de ácidos grasos de cadena larga n-3 y n-6 (ácido eicosapentanoico (EPA), el ácido docosahexanoico (DHA) y el ácido gamma-linoleico (GLA)) suplementados diariamente con dosis alta de EPA y al menos cuatro meses.

PDF

Referencias

Montañés-Rada F, Gastaminza-Pérez X, Catalá MA, Ruiz-Sanz F, Ruiz-Lázaro PM, Herreros-Rodríguez O, et al; Grupo de Especial Interés en el TDAH (GEITDAH). Consenso del GEITDAH sobre el trastorno por déficit de atención/hiperactividad. Rev Neurol 2010; 51: 633-637.

Bartl J, Walitza S, Grünblatt E. Enhancement of cell viability after treatment with polyunsaturated fatty acids.Neurosci Lett 2014; 24; 559: 56-60.

Ruiz-Lázaro PM, Argemí M. Tratamiento no farmacológico en el trastorno por déficit de atención con y sin hiperactividad (TDAH). Trabajo social y salud 2009; 62: 115-120.

Skokauskas N, McNicholas F, Masaud T, Frodl T. Complementary medicine for children and young people who have attention deficit hyperactivity disorder. Curr Opin Psychiatry 2011; 24 (4):291-300.

Martí LF. Effectiveness of nutritional interventions on the functioning of children with ADHD and/or ASD. An updated review of research evidence. Bol Asoc Med P R 2010; 102 (4): 31-42.

Millichap JG, Yee MM. The diet factor in attention-deficit/hyperactivity disorder. Pediatrics 2012; 129 (2): 330-337.

Hurt EA, Arnold LE, Lofthouse N. Dietary and nutritional treatments for attention-deficit/ hyperactivity disorder: current research support and recommendations for practitioners. Curr Psychiatry Rep 2011; 13 (5):323-332.

Rojas NL, Chan E. Old and new controversies in the alternative treatment of Attention-Deficit Hyperactivity Disorder. Ment Retard Dev Disab Res Rev 2005; 11 (2): 116-130.

Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der Oord S, Döpfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski T, Buitelaar J, Coghill D, Hollis C, Konofal E, Lecendreux M, Wong IC, Sergeant J; European ADHD Guidelines Group. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 2013; 170: 275-289.

Grassmann V, Santos-Galduróz RF, Galduróz JC. Effects of low doses of polyunsaturated Fatty acids on the attention deficit/hyperactivity disorder of children: a systematic review. Curr Neuropharmacol 2013; 11 (2):186-196.

Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 2001; 65 (1):1-7.

Bennett CN, Horrobin DF. Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. Prostaglandins Leukot Essent Fatty Acids 2000; 63 (1-2):47-59.

Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005; 65 (8):1051-9.

Lavialle M, Denis I, Guesnet P, Vancassel S. Involvement of omega-3 fatty acids in emotional responses and hyperactive symptoms. J Nutr Biochem 2010; 21(10): 899-905.

Kidd PM. Omega-3 DHA and EPA for Cognition, Behavior, and Mood: Clinical Findings and Structural-Functional Synergies with Cell membrane Phospholipids. Alternative Medicine Review 2007; 12 (3): 207-227.

Johnson M, Ostlund S, Fransson G, Kadesjö B, Gillberg C. Omega-3/Omega-6 Fatty Acids for Attention Deficit Hiperactivity Disorder. A Randomized Placebo-Controlled Trial in Children and Adolescents J Atten Disord 2009; 12 (5): 394-401.

Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007; 28 (2):82-91.

Sinn N, Bryan J, Wilson C. Cognitive effects of polyunsatured fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukot Essent Fatty Acids 2008; 78 (4-5): 311-326.

Richardson AJ. Omega-3 fatty acid in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006;18 (2): 155-172.

Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and wich fatty acid?. Lipids in Health and Disease 2007; 6 (21).

Quintero J, Rodriguez-Quirós J, Correas-Lauffer J, Pérez-Templado J. Aspectos nutricionales en el trastorno por déficit de atención/hiperactividad. Rev Neurol 2009; 49 (6): 307-312.

Transler C, Ellander A, Mitchell S, van de Meer N. The impact of polyunsatured fatty acids in reducing child attention deficit and hiperactivity disorders. J Atten Disord 2010; 14 (3): 232-246.

Huss M, Volp A, Stauss-Grabo M. Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attentiondeficit/ hyperactivity problems- an observational cohort study. Lipids in Health and Disease 2010; 9:105.

Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, Richter Y, Zaaroor-Regev D, Manor Y, Weizman A. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry 2012; 27 (5): 335-342.

Gustafsson PA, Birberg-Thomberg U, Duchén K, Landgren M, Malmberg K, Pelling H, Strandvik B, Karlsson T. EPA supplementation improves teacher–rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr 2010; 99 (10): 1540-1549.

Raz R, Gablis L. Essential fatty acids and attentiondeficit-hipercativity disorder:a systematic review. Dev Med Child Neurol 2009; 51 (8): 580-592.

Politi P, Rocchetti M, Emanuele E, Rondanelli M, Barale F. Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: a Review of Current Literature. Curr Drug Discov Technol 2013; 10 (33): 245-253.

Bloch MH, Qawasmi A.Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and metaanalysis. J Am Acad Child Adolesc Psychiatry 2011; 50 (10): 991-1000.

Milte CM, Sinn N, Buckley JD, Coates AM, Young RM, Howe PR. Polyunsaturated fatty acids, cognition and literacy in children with ADHD with and without learning difficulties. J Child Health Care 2011; 15 (4): 299-311.

Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PR. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition 2012; 28 (6): 670-677.

Richardson AJ. Review: ω-3 fatty acids produce a small improvement in ADHD symptoms in children compared with placebo. Evid Based Ment Health 2012; 15 (2) 46.

Searight HR, Robertson K, Smith T, Perkins S, Searight BK. Complementary and alternative therapies for pediatric attention deficit hyperactivity disorder: a descriptive review. ISRN Psychiatry 2012; 2012: 804127.

Richardson AJ, Burton JR, Sewell RP, Spreckelsen TF, Montgomery P. Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study). PLoS One 2012; 7(9): e43909.

Montgomery P, Burton JR, Sewell RP, Spreckelsen TF, Richardson AJ. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: a crosssectional analysis from the DOLAB study. PLoS One 2013; 8 (6): e66697

Kean JD, Camfield D, Sarris J, Kras M, Silberstein R, Scholey A, Stough C. A randomized controlled trial investigating the effects of PCSO-524(R), a patented oil extract of the New Zealand green lipped mussel (perna canaliculus), on the behaviour, mood, cognition and neurophysiology of children and adolescents (aged 6--14 years) experiencing clinical and sub-clinical levels of hyperactivity and inattention: study proocol ACTRN12610000978066. Nutr J 2013; 12 (1):100.

Bioque M, Goti J, Capapeya J, Bernardo M. Eficacia de los ácidos grasos omega-3 como tratamiento suplementario en la esquizofrenia Psiq Biol 2013; 20 (1-2): 8-13.

Descargas

Los datos de descarga todavía no están disponibles.